Big Pharma is facing a multi-county legal smackdown in Michigan, as Metro Detroit local governments have united to file lawsuits against top pharmaceutical companies over the sky-high prices of insulin. Wayne, Washtenaw, Macomb, and Monroe counties have launched legal action accusing drug manufacturers and pharmacy benefit managers of price-fixing for the life-saving medication, reports the Detroit News.
The complaints, which were filed in the U.S. District Court for the District of New Jersey, claim these corporations have colluded to artificially increase the cost of insulin, thereby burdening patients and straining county budgets. Allegations cite not only an egregious jump in prices but also a calculated effort to conceal rebate amounts and continuously inflate insulin costs - a scheme that is expected to have caused financial injury spanning two decades. "Wayne County pays an awful lot of money for drugs, particularly insulin in this case for its employees, and we've been gouged and we know we've been gouged, and that money needs to be recouped," Wayne County Executive Warren Evans told the Detroit News.
Detroit's Mayor, Mike Duggan, also joined the chorus of disapproval, signaling the city's intent to follow suit in filing similar legal challenges. During a news conference at the Detroit Rescue Mission Ministries, he lamented the financial pressures faced by the city's residents, one in six of whom are wrestling with diabetes. Drawing parallels to federal action, the Biden administration's cap on Medicare insulin out-of-pocket costs was highlighted as a benchmark that ought to be extended to all, not just the Medicare recipients, Echoing these sentiments, attorney Melvin Butch Hollowell, representing the counties, highlighted that "the pharmacies and manufacturers get together. They control about 90% of the market each, of the insulin market. They talk to each other secretly. And they jack up the prices through anticompetitive means," as per a Detroit Free Press report.
Despite the allegations, pharmaceutical companies have pushed back, with Sanofi and Novo Nordisk asserting their compliance with the law and framing their pricing practices within the complexities of the U.S. health care system's rebate structure. The defendants stated their commitment to providing affordable insulin through various programs, a stance that Novo Nordisk reasserted in defense against the lawsuit, as were to cite a clickondetroit statement.
With the legal battle shaping up to potentially mirror the drawn-out opioid litigation that only recently began paying out to Michigan municipalities, the current suits look to force a change not only in the cost but also in the transparency of insulin pricing. It's not just about winning back dollars, it's about addressing a crucial public health concern where some, like Detroit Rescue Mission Ministries' Angela Moye, say they’ve had to make the tough choice between purchasing medication and feeding their children. As Detroit and neighboring counties brace for a prolonged legal showdown, all eyes will be on how this David-vs-Goliath scenario unfolds in the courts.
